RSS-Feed abonnieren
DOI: 10.1055/s-0043-114416
Das Parsonage-Turner-Syndrom
Parsonage-Turner Syndrome – Case ReportPublikationsverlauf
Publikationsdatum:
19. September 2017 (online)
![](https://www.thieme-connect.de/media/zfo/201706/lookinside/thumbnails/10-1055-s-0043-114416_ou5203-1.jpg)
Zusammenfassung
Die neuralgische Schultermyatrophie (Parsonage-Turner-Syndrom) ist eine selten auftretende, akute periphere Neuropathie des Plexus cervicobrachialis. Die genaue Ursache der Erkrankung ist nicht bekannt. Die Diagnose kann aufgrund der Anamnese und körperlichen Untersuchung gestellt werden. Ergänzend ist die Durchführung einer Magnetresonanztomografie (MRT) der betroffenen Schulter und ggf. der HWS zum Ausschluss konkurrierender Ursachen sinnvoll. Eine spezifische Therapie existiert nicht. Die Erkrankung heilt in Abhängigkeit von der Intensität der Erstmanifestation in etwa 50 – 67% der Fälle innerhalb von 2 bis 3 Jahren aus. Bei unvollständiger Erholung können neurologische Defizite verbleiben, insbesondere nach wiederholten Attacken an derselben Extremität.
Abstract
Neuralgic amyotrophy of the shoulder (Parsonage-Turner syndrome) is a rare condition of unknown aetiology which manifests as acute neuropathy of the brachial plexus. Diagnosis is based on typical symptoms and physical examination. In addition, magnetic resonance imaging of the affected shoulder and the cervical spine is advisable, in order to distinguish this syndrome from other conditions with similar symptoms. There is no specific treatment for neuralgic amyotrophy, but in about 50 – 67% of cases complete recovery occurs within two to three years, depending on the severity of the symptoms when they first appear. In patients whose strength and function are not fully restored, neurological deficits may remain, especially if the same shoulder is affected by recurrent attacks.
-
Literatur
- 1 Van Alfen N, van Eijk JJ, Ennik T. et al. Incidence of neuralgic amyotrophy (parsonage turner syndrome) in a primary care setting – a prospective cohort study. PLoS One 2015; 10: 0128361
- 2 Van Alfen N, van Engelen BG, Reinders JW. et al. The natural history of hereditary neuralgic amyotrophy in the Dutch population: two distinct types?. Brain 2000; 123: 718-723
- 3 Hussey AJ, OʼBrien CP, Regan PJ. Parsonage-Turner syndrome – case report and literature review. Hand (N Y) 2007; 2: 218-221
- 4 Parsonage MJ, Turner JW. Neuralgic amyotrophy: The shoulder-girdle syndrome. Lancet 1948; 251: 973-978
- 5 Van Alfen N. The neuralgic amyotrophy consultation. J Neurol 2007; 254: 695-704
- 6 Van Alfen N, van Engelen BG. The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain 2006; 129: 438-450
- 7 Van Eijk JJ, van Alfen N, Berrevoets M. et al. Evaluation of prednisolone treatment in the acute phase of neuralgic amyotrophy: an observational study. J Neurol Neurosurg Psychiatry 2009; 80: 1120-1124
- 8 Feinberg JH, Radecki J. Parsonage-Turner syndrome. HSS J 2010; 6: 199-205
- 9 Van Alfen N. Clinical and pathophysiological concepts of neuralgic amyotrophy. Nat Rev Neurol 2011; 7: 315-322
- 10 Van Alfen N, van Engelen BG, Hughes RA. Treatment for idiopathic and hereditary neuralgic amyotrophy (brachial neuritis). Cochrane Database Syst Rev 2009; (03) CD006976
- 11 Gupta A, Winalski CS, Sundaram M. Neuralgic amyotrophy (Parsonage Turner syndrome). Orthopedics 2014; 37: 75-133
- 12 Geertzen JH, Groothoff JW, Nicolai JP. et al. Brachial plexus neuropathy. A long-term outcome study. J Hand Surg 2000; 25: 461-464
- 13 England JD. The variations of neuralgic amyotrophy. Muscle Nerve 1999; 22: 435-436